AWMSG publishes Annual Report 2021–2022
Find out about all the projects the All Wales Medicines Strategy Group (AWMSG) has been working on throughout 2021-2022 in their latest annual report, compiled by the All Wales Therapeutics and Toxicology Centre (AWTTC).
In it we highlight the outputs from the nine virtual AWMSG meetings held during the year, including:
- 21 medicines appraised (8 full submissions, 4 limited submissions and 9 paediatric licence extensions)
- 17 Statements of Advice issued
- 14 medicine optimisation resources published
- 15 national prescribing indicators monitored throughout the year
- 9 Wales Patient Access Schemes processed.
The report also outlines the important work AWMSG carries out with the three main partner groups – patients and the public, healthcare professionals and the pharmaceutical industry – as it and AWTTC continues to respond to the challenges of the pandemic while supporting the safe and prudent prescribing of medicines.
It also reports on the many achievements of AWMSG and AWTTC over the last year, despite the difficulties of the pandemic.
Professor Iolo Doull, Chair of AWMSG, said: "The period from 1st April 2021 to 31st March 2022 has been challenging but interesting.
"I’ve been heartened to see how we have been able to adapt our work to meet the challenges of a protracted COVID-19 global pandemic and the resilience and innovation that has been shown by all staff working within NHS Wales and in social care.
"The central role that medicines have played throughout the pandemic highlights the importance of the work that AWMSG and its sub-groups, the All Wales Prescribing Advisory Group (AWPAG) and the New Medicines Group (NMG), does in advising Welsh Government and supporting colleagues with prescribing and medicines management.
"The support provided by the multi-disciplinary team working within AWTTC, based in the Routledge Academic Centre in the University Hospital Llandough, has been invaluable and unique."
Read the full 2021–2022 AWMSG Annual Report